Evidence map›Paper›PMID 35710087›Full record

ArticleOphthalmology. Glaucoma

Longitudinal Structure-Function Relationship between Macular Vessel Density and Thickness and Central Visual Field in Early Glaucoma.

Vahid Mohammadzadeh, Sasan Moghimi, Takashi Nishida, James A Proudfoot, Medi Eslani, Alireza Kamalipour, Nevin El-Nimri, Eleonora Micheletti, Linda M Zangwill, Robert N Weinreb

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology. Glaucoma. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Ocular microvascular changes in hypoestrogenism: an OCT/OCTA systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Vahid MohammadzadehHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California.
Sasan MoghimiHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California.
Takashi NishidaHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California.
James A ProudfootHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California.
Medi EslaniHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California.
Alireza KamalipourHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California.
Nevin El-NimriHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California.
Eleonora MichelettiHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California.
Linda M ZangwillHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California.
Robert N WeinrebHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California; University of California, San Diego, La Jolla, California. Electronic address: rweinreb@ucsd.edu.

Funding

African Descent And Glaucoma Evaluation Study (ADAGES)U10EY014267 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 2002 to 2010
$13.2M
Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Derek Stuart Welsbie · 2012 to 2026
$10.3M
Diagnostic Innovations in Glaucoma:Structural AssessmentR01EY011008 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 1995 to 2015
$8.7M
Diagnostic Innovations in Glaucoma Study (DIGS): High Myopia and Advanced DiseaseR01EY027510 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LINDA M ZANGWILL · 2017 to 2026
$5.3M
Diagnosis and Monitoring of Glaucoma with Optical Coherence Tomography AngiographyR01EY029058 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WEINREB, ROBERT N · 2018 to 2024
$4.2M
African Descent and Glaucoma Evaluation (ADAGES) II: Glaucoma ProgressionR01EY019869 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 2010 to 2014
$2.8M
African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the lamina cribrosa in progressionR01EY026574 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FAZIO, MASSIMO ANTONIO, GIRKIN, CHRISTOPHER ANTHONY · 2017 to 2020
$2.6M
NEI NIH HHS P30 EY022589NEI NIH HHS R01 EY011008NEI NIH HHS R01 EY019869NEI NIH HHS R01 EY026574NEI NIH HHS R01 EY027510NEI NIH HHS R01 EY029058NEI NIH HHS U10 EY014267
6 · The paper itself

Abstract

purposeTo investigate the relationship of longitudinal changes in macular vessel density (VD) from OCT angiography and in ganglion cell complex (GCC) from OCT with central visual field (VF) in eyes with early glaucoma.

designObservational cohort.

participantsA total of 95 eyes, 37 preperimetric and 58 with early glaucoma (24-2 VF mean deviation [MD] ≥ -6 decibels), with an average follow-up of 3.8 years and 5.3 visits, were included.

methodsWhole-image VD (wiVD) and whole-image GCC (wiGCC) and parafoveal scans, as well as localized regions of interest (LROIs), hemiretinae of whole images, and superior, inferior, temporal, and nasal sectors of parafoveal maps, were matched with central VF locations. Age-adjusted rates of change of VD, GCC, mean sensitivity of VF locations, and 10-2 VF MD were calculated using linear mixed-effect models. Normalized rates of change were calculated for comparison of change rates in wiVD and wiGCC.

main outcome measuresStructure-function (SF) correlations of VD and GCC with central VF measurement change rates and comparison of different correlations of SF relationships after bootstrapping the difference of the correlation coefficients.

resultsVessel density loss and GCC thinning demonstrated significant correlations with central VF damage, globally and with most LROIs. The SF correlation (r, 95% confidence interval [CI]) between wiVD and 10-2 VF MD change rates was 0.42 [0.24, 0.58], whereas it was 0.27 [0.08, 0.45] between wiGCC and 10-2 VF MD changes rates (all P < 0.05). In contrast to GCC thinning, VD loss in the parafoveal sectors demonstrated significant correlations with central VF damage in inferior and temporal sectors. Differences in the relationship of SF with central VF damage were not significant between VD loss and GCC thinning. The mean (95% CI) normalized change rates of wiVD (-7.40 [-7.71 to 7.09] %/year) was faster than that of wiGCC (-2.39 [-2.94 to 1.84] %/year) (P < 0.05).

conclusionsRates of VD loss and GCC thinning are associated with central VF loss over time. Assessment of both macular VD and GCC thickness should be considered for evaluation of glaucoma progression.

Indexed as

GlaucomaGlaucoma, Open-AngleOptic DiskFluorescein AngiographyHumansIntraocular PressureNerve FibersRetinal Ganglion CellsRetinal VesselsStructure-Activity RelationshipTomography, Optical CoherenceVisual FieldsVisual Field TestsCentral visual fieldGanglion cell complexLongitudinal structure–functionMacular vessel densityOCT angiography

Identifiers

PMID35710087
PMCPMC10593185

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.